VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.23. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 3.34% in last session and finished the day at $ 5.26. Traded volume was 2,821,422 shares in the last session and the average volume of the stock remained 3,442,280 shares. The beta of the stock remained 1.53. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Span-America Medical Systems, Inc. (NASDAQ:SPAN)reported its results for the second fiscal quarter ended March 29, 2014. Net income for the second quarter of fiscal 2014 was $891,000, or $0.30 per diluted share, compared with $1.2 million, or $0.41 per diluted share, in the second quarter of fiscal 2013. Net sales for the second quarter of fiscal 2014 were $14.7 million compared with $16.6 million in the second quarter of fiscal 2013. Span-America Medical Systems, Inc. (NASDAQ:SPAN)rose 1.29% percent to $ 21.25 Friday on volume of 16,099 shares. The intra-day range of the stock was $ 20.70 – 21.38. Span-America Medical Systems, Inc. (NASDAQ:SPAN)has a market capitalization of $ 62.92 million.

Cyberonics, Inc. (NASDAQ:CYBX)’s CFO Gregory Browne sold 1,500 shares of Cyberonics stock on the open market in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $61.61, for a total value of $92,415.00. Following the sale, the chief financial officer now directly owns 63,442 shares in the company, valued at approximately $3,908,662. Cyberonics, Inc. (NASDAQ:CYBX)’s stock on May 2, 2014 reported an increase of 2.68% to the closing price of $ 62.12. Its fifty two weeks range is $ 42.51 – 73.52. The total market capitalization recorded $ 1.67 billion. The overall volume in the last trading session was 672,305 shares. In its share capital, Cyberonics, Inc.(NASDAQ:CYBX) has 26.83 million outstanding shares.

RXi Pharmaceuticals Corp (NASDAQ:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI‑109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to build the Company’s ophthalmology franchise. On Friday, shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) advanced 6.62% to close the day at $ 3.38. Company return on investment (ROI) is -720.70% and its monthly performance are recorded as -22.83%. RXi Pharmaceuticals Corp (NASDAQ:RXII) quarterly revenue growth is -27.31%.